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a  b  s  t  r  a  c  t
Background:  Comparative  data  on  severity  and  treatment  of  seasonal,  pandemic  and  post-pandemic
inﬂuenza  virus  infections  are  scarce.
Objectives:  To  systematically  analyze  characteristics  of  hospitalized  patients  with  inﬂuenza  in the  post-
pandemic  period  compared  to seasonal  and  pandemic  inﬂuenza.
Study  design:  Clinical  and  virological  data  of  patients  hospitalized  in  a tertiary  referral  hospital  with
post-pandemic  inﬂuenza  (2010–2011)  were  compared  with  those  during  seasonal  inﬂuenza  epidemics
(2007–2009)  and  the  inﬂuenza  A(H1N1)pdm09  pandemic  (2009–2010).
Results:  82  patients  were  admitted  during  the  post-pandemic  period,  compared  to  85  during  the pandemic
and  60  during  seasonal  inﬂuenza  epidemics.  No  differences  were  observed  in  the occurrence  of  compli-
cated  illness  and  the need  for  intensive  care.  However,  radiographic  pneumonia  was  signiﬁcantly  more
often  diagnosed  in  patients  with  inﬂuenza  A(H1N1)pdm09  compared  to  patients  with  seasonal  inﬂuenza
A  (25%  versus  71%  in pandemic,  p  = 0.004,  and  55%  in  post-pandemic,  p = 0.047).  Oseltamivir  was  more
frequently  prescribed  in  post-pandemic  and  pandemic  patients  compared  to previous  inﬂuenza  seasons
(48.9%  resp.  76.5%  versus  6.5%, p  < 0.0001).  During  the post-pandemic  period,  patients  with  inﬂuenza
B  were  signiﬁcantly  less  often  treated  with  oseltamivir  compared  to patients  with  inﬂuenza  A (27.0%
versus  48.9%,  p = 0.043),  although  the  course  of  illness  in patients  with  inﬂuenza  B  was comparable  with
inﬂuenza  A. No  upsurge  of  oseltamivir  resistance  was observed.
Conclusions:  In  our  center,  severity  of  illness  was  comparable  for  all  inﬂuenza  seasons,  although  more
radiographic  pneumonia  was  diagnosed  in patients  with  inﬂuenza  A(H1N1)pdm09.  Despite  the  increased
use of  oseltamivir,  no increase  in  oseltamivir  resistance  was  detected.
© 2012 Elsevier B.V. All rights reserved.. Background
In March 2009 a novel inﬂuenza A H1N1 virus ‘inﬂuenza
(H1N1)pdm09’ emerged and rapidly spread around the world
ausing the ﬁrst pandemic of this century. Although severe ill-
ess and death have been reported, it was mostly regarded as
 relatively mild disease, with a course of illness comparable
o seasonal inﬂuenza.1–4 Historically, inﬂuenza in the immediate
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oi:10.1016/j.jcv.2012.02.010post-pandemic period has been known to be able to cause severe
morbidity and mortality.5 Indeed, some countries reported a
more severe inﬂuenza season in 2010–2011 compared to the
pandemic waves.6 However, data based on systematic analysis
of the impact of inﬂuenza in the post-pandemic period are
scarce.
2. Objectives
In order to compare the characteristics of inﬂuenza in
hospitalized patients in the post-pandemic period to those with
seasonal and pandemic inﬂuenza, we  systematically collected clin-
ical information of patients hospitalized in a tertiary referral
hospital with inﬂuenza from 2007 to 2011.







































BFig. 1. Inﬂuenza (sub)type distribut
. Study design
.1. Study population
A retrospective observational study was conducted in all
atients with inﬂuenza infection hospitalized in the University
edical Center Groningen (UMCG) from August 2007 till July 2011.
atients with acute respiratory illness were tested; only patients
ith real-time PCR (RT-PCR) conﬁrmed inﬂuenza were included
n the study. The UMCG is a large tertiary referral hospital with
ver 1300 beds in the northern region of the Netherlands. Patients
ere divided into three cohorts: patients with seasonal inﬂuenza
August 2007–May 2009), patients with pandemic inﬂuenza (June
009–July 2010) and those with inﬂuenza during the ﬁrst post-
andemic season (August 2010–July 2011). We  compared clinical,
pidemiological and virological data of patients with conﬁrmed
nﬂuenza A separately from those with inﬂuenza B infection.
.2. Clinical data and deﬁnitions
Clinical information was gathered using a standardized ques-
ionnaire, including clinical symptoms, underlying chronic illness,
edical complications, and treatment. Inﬂuenza vaccination his-
ory was initially included in the questionnaire, however because
his was poorly documented in patients records, it had to be
xcluded for analysis. Complications were listed as pulmonary
pneumonia, respiratory insufﬁciency, pneumothorax, other pul-
onary symptoms) or extra-pulmonary (renal failure, sepsis,
eurological symptoms). Radiographic ﬁndings were classiﬁed into
nﬁltrates, pleural effusion, interstitial abnormalities and pneu-
othorax. Bacterial co-infection was deﬁned by isolation of a
igniﬁcant pathogen in respiratory or blood samples of a patient
ithin 3 days before or after the detection of inﬂuenza. Time from
nset of symptoms to admission and to sample date was  calculated
or each patient.
.3. Laboratory methods
Nasopharyngeal swabs or nasopharyngeal aspirates were taken
or the detection of respiratory viruses by a laboratory devel-
ped RT-PCR as has been described before.7,8 In 11% of patients,
putum was used. Identiﬁcation of inﬂuenza types and subtypes
uring 2007–2011 was performed as described elsewhere.9–12 In
hort, RNA was isolated using the NucliSense EasyMag (bioMérieux,
yon, France), or Magna Pure LC Total Nuclei Acid Isolation kit
ith external lysis protocol (Roche Diagnostics, Indianapolis, USA).
oth inﬂuenza A and inﬂuenza B were detected by generic RT-PCRring inﬂuenza seasons 2007–2011.
assay targeting the matrix gene. Multiple primers were used for
screening and subtyping (Table 1). All inﬂuenza A(H1N1) positive
samples were subsequently screened for the presence of the H275Y
mutation in the neuraminidase gene (N1 nomenclature), conferring
full resistance to oseltamivir.12
3.4. Statistical analysis
Statistical analyses were performed using SPSS version 18.0
(Chicago, USA). Interseasonal comparisons were tested using Mann
Whitney U test and Fisher’s exact test for continuous variables.
Dichotomous variables were tested using 2 test. The effect of age
on outcome was analyzed using multinomial logistic regression,
for which each cohort was  divided in two  groups: patients under
the age of 15 and those above. P values ≤0.05 were considered as
statistically signiﬁcant.
4. Results
A  total of 227 patients with conﬁrmed inﬂuenza were included
in the study: 60 patients during the pre-pandemic seasons (47
with inﬂuenza A, of which 33 with inﬂuenza A(H3N2)), 85 dur-
ing the pandemic (all inﬂuenza A(H1N1)pdm09), and 82 in the
post-pandemic period (45 with inﬂuenza A(H1N1)pdm09, 37 with
inﬂuenza B) (Fig. 1). For analysis, the pre-pandemic seasons
(2007–2009) were compiled as no signiﬁcant differences were
observed with regard to patients’ characteristics, course of illness
and clinical outcomes (data not shown).
4.1. Inﬂuenza A
Characteristics of patients with inﬂuenza A are summarized in
Table 2. No signiﬁcant differences were observed in gender ratio,
although there was  a tendency toward more male patients admit-
ted during the pandemic and post-pandemic period (57.6% and
55.6% versus 42.7% during seasonal inﬂuenza, p = 0.11 resp. p = 0.30)
Age distribution among patients with seasonal, pandemic and post-
pandemic inﬂuenza A differed signiﬁcantly (Table 3). Forty percent
of patients hospitalized with seasonal inﬂuenza A were aged
under 4 years, signiﬁcantly more than during the post-pandemic
period (20%, p = 0.03). During the pandemic, a shift toward young
adolescents was  observed: almost 25% of patients with pan-
demic inﬂuenza A were aged 5–14 years, signiﬁcantly more than
during seasonal and post-pandemic inﬂuenza. In the post-
pandemic period more patients aged 15–64 years were admitted
(71%) compared to patients with seasonal inﬂuenza (38%, p = 0.002)
and with pandemic inﬂuenza (45%, p = 0.004).
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Table  1
Primers used for screening and identiﬁcation of inﬂuenza viruses used in this study (with adjustments from April 2011 onwards).
Target Aim Primer Oligotide sequence 5′ ⇒ 3′ and labels
InfA Screening INFA-asense-TM CAAAGCGTCTACGCTGCAGTCC
infA-probe-2 FAM-TTTGTGTTCACGCTCACCGTGCC-BHQ1
04/18/11 INFA-sense-TM AAGACCAATCCTGTCACCTCTGA




































Overview of inﬂuenza A cohorts as described in this study.
Seasonal inﬂuenza A (n = 47) Pandemic inﬂuenza A (n = 85) Post-pandemic inﬂuenza A (n = 45)
Inﬂuenza A subtypes (absolute numbers)
H1N1 7 0 0
H3N2 33 0 0
H1N1nv 0 85 41
Non  typable inﬂuenza A 7 0 4
Male  gender (%) 42.6 57.6 55.6
Median age in years (IQR) 21.3 (1.1–59.5) 14.2 (4.6–48.5) 49.8* (14.9–59.5)
Underlying medical condition (%) 87.2** 70.6 80.0
Timespan, median in days (IQR)
From symptom onset to admission 2.5 (1.0–4.0) 2.0 (1.0–4.0) 1.0¶ (0.0–3.0)
From  symptom onset to sample date 4.0† (2.0–6.0) 2.0 (1.0–4.0) 2.0 (1.0–4.0)
Hospital length of stay 8.0 (5.0–14.0) 6.0 (2.0–14.5) 6.0 (3.0–20.5)
Received oseltamivir therapy (%) 6.5 76.5§ 48.9
Resistance to oseltamivir (absolute numbers) 4 4 1
Admitted to ICU (%) 25.5 29.4 22.2
Experienced complications (%) 38.3 49.4‡ 40.0
Death (absolute numbers) 3 7 3
IQR = interquartile ranges.
* p = 0.004 post-pandemic inﬂuenza A versus pandemic inﬂuenza A.
** p = 0.03 seasonal inﬂuenza A versus pandemic inﬂuenza A.





t† p = 0.02 seasonal inﬂuenza A versus pandemic inﬂuenza A, p = 0.008 seasonal in
§ p < 0.0001 pandemic inﬂuenza A and post-pandemic inﬂuenza A versus seasona
‡ p = 0.2 pandemic inﬂuenza A versus seasonal inﬂuenza A.The course of illness in patients with inﬂuenza A was similar
or all seasons. No signiﬁcant differences were observed in the
ccurrence of complicated illness and the need for admission
o the intensive care unit (ICU), also after adjustment for thea A versus post-pandemic inﬂuenza A.
enza A, p = 0.001 pandemic inﬂuenza A versus post-pandemic inﬂuenza A.differences in age distribution (Table 2). During all seasons, patients
were admitted to the hospital within a median time of 3 days after
onset of symptoms, independent of the presence of complicated ill-
ness or necessity for ICU admittance. No differences in duration of
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Table  3
Age distribution in patients with seasonal, pandemic and post-pandemic inﬂuenza A.
Seasonal inﬂuenza A (n = 22) Pandemic inﬂuenza A (n = 44) Post-pandemic inﬂuenza A (n = 11)
0–4 years 40.4% 21.7% 20.0%*
5–14 years 6.4% 24.7%** 4.4%
15–64  years 38.3% 44.7% 71.1%†
>65 years 14.9%§ 3.5% 4.4%




















































wp = 0.004 pandemic inﬂuenza A versus post-pandemic inﬂuenza A, p = 0.009 pan
† p = 0.002 post-pandemic inﬂuenza A versus seasonal inﬂuenza A, p = 0.004 post
§ p = 0.02 seasonal inﬂuenza A versus pandemic inﬂuenza A.
ospitalization were seen; only complicated illness was associated
ith a longer hospital stay (p < 0.0001, data not shown). In patients
dmitted during the pandemic and post-pandemic period, respira-
ory samples for the detection of inﬂuenza were taken signiﬁcantly
ore rapidly compared to patients admitted in previous inﬂuenza
easons.
Chronic underlying illness was signiﬁcantly less present in
atients with pandemic inﬂuenza A compared to those with sea-
onal inﬂuenza A (70.6% versus 87.2%, p = 0.03). However, when
djusted for age, no signiﬁcant differences of comorbidities were
etected among the three inﬂuenza periods in patients over
5 years. In both the pandemic and post-pandemic period, comor-
idities were signiﬁcantly less present in patients under the age
f 15: 59.1% with pandemic inﬂuenza A (p = 0.025) and 54.4%
ith post-pandemic inﬂuenza A (p = 0.044) compared to 86.4% of
atients with seasonal inﬂuenza A.
The most remarkable differences however were seen in
seltamivir treatment: oseltamivir was more frequently prescribed
n pandemic patients compared to previous inﬂuenza seasons
76.5% versus 6.5%, p < 0.0001). In the post-pandemic period, pre-
cription rates diminished although still more patients received
ntiviral therapy compared to those with seasonal inﬂuenza A
48.9% versus 6.5%, p < 0.0001). These differences remained after
djustment for the differences in age distribution.
During the pandemic, patients not treated with oseltamivir were
igniﬁcantly younger, had less chronic underlying illness, were
dmitted to the hospital later in the course of illness and had to
tay hospitalized relatively shortly compared to those who were
reated with oseltamivir. Also, patients not treated with oseltamivir
ere less frequently admitted to the ICU (Table 4). During the post-
andemic period however, these differences between patients with
nd without oseltamivir treatment were not observed. Despite
he strong increase in oseltamivir treatment, no increase in
seltamivir resistance was detected. During the seasonal inﬂuenza
eriod, all oseltamivir resistant inﬂuenza A were subtyped as
nﬂuenza A(H1N1), as was expected considering reports of emerg-
ng oseltamivir-resistant seasonal inﬂuenza A(H1N1) since 2007.13
uring the pandemic and post-pandemic period, four out of ﬁve
atients developed oseltamivir resistance while being treated with
seltamivir; one patient was infected with primarily oseltamivir
esistant inﬂuenza A(H1N1)pdm09.
Chest radiographs were performed in 68%, 67% and 76% of
atients with seasonal, pandemic and post-pandemic inﬂuenza A
espectively. Radiographic abnormalities were reported in similar
requencies in pandemic and post-pandemic inﬂuenza A (60% and
9%), more than in seasonal inﬂuenza A (37.5%) although statistical
igniﬁcance could not be reached. Compared to seasonal inﬂuenza
 however, radiographic pneumonia (25% in seasonal inﬂuenza A)
as more often diagnosed in patients during the pandemic (71%,
 = 0.004) and post-pandemic period (55%, p = 0.047). No signiﬁcant
ifferences were seen in isolated bacterial pathogens between all
nﬂuenza seasons. Also, no difference was seen in the prescription
ate of antibiotics: during all seasons approximately 70% of patients
ere treated with antibiotics.c inﬂuenza A versus seasonal inﬂuenza A.
emic inﬂuenza A versus pandemic inﬂuenza A.
4.2. Inﬂuenza B
In the study period, 50 patients were included with conﬁrmed
inﬂuenza B infection, 13 during pre-pandemic seasons, and 37
during the post-pandemic period. No differences were seen in
patients’ characteristics and course of illness between patients
with post-pandemic inﬂuenza B compared to those with seasonal
inﬂuenza B. The clinical characteristics of patients with inﬂuenza B
were remarkably similar to those with inﬂuenza A (Table 5). How-
ever, during the post-pandemic period, patients with inﬂuenza B
were signiﬁcantly less often treated with oseltamivir compared to
patients with inﬂuenza A (27.0% versus 48.9%, p = 0.043). Patients
with post-pandemic inﬂuenza B were admitted later in the course
of illness (median 3 versus 2.5 days, p = 0.028) and were also
tested later for the presence of inﬂuenza (median 4 versus 3 days,
p = 0.006).
5. Discussion
Our study is one of the ﬁrst to systematically assess the clini-
cal, epidemiological and virological characteristics of patients with
post-pandemic inﬂuenza. Inﬂuenza in the post-pandemic period,
including both inﬂuenza A and inﬂuenza B, was in our center
equally severe as the pandemic in terms of the number of patients
admitted. The course of illness in patients with inﬂuenza A was
comparable for all seasons, indicating no increased severity of
inﬂuenza A(H1N1)pdm09 compared to other inﬂuenza A sub-
types. Besides, patients with inﬂuenza B displayed similar clinical
characteristics as those with inﬂuenza A. However, several aspects
are noteworthy.
The age distribution of patients admitted with inﬂuenza dif-
fered signiﬁcantly in the three study periods. Patients with seasonal
inﬂuenza displayed the well known age distribution with relatively
more infections in the young (<4 years) and the old (> 65 years)
compared to pandemic and post-pandemic periods. During the
pandemic, a shift was  noticed toward the school-aged and ado-
lescent population, as has been described by others.2,14,15 The
relative lower risk of infection among older individuals has been
explained by the presence of cross reactive antibodies due to expo-
sure to circulating descendants of the 1918 H1N1 pandemic virus
before 1957.16 The majority of hospitalized patients in the imme-
diate post-pandemic period were signiﬁcantly older compared to
those admitted during the pandemic. Children might have been
less susceptible for serious infection during the post-pandemic
period because of a relatively high attack rate during the previ-
ous pandemic inﬂuenza season or to persisting vaccine-induced
immunity.17. In the Netherlands, vaccination strategy during the
pandemic focused on risk groups and young children below the age
of four. Vaccination coverage among children reached around 60%
in the northern region of the Netherlands (personal communication
B. Wolters, Municipal Health Service Groningen).
During all seasons patients were admitted relatively early in
the course of illness. These ﬁndings suggest that serious illness is
mainly due to effects of the inﬂuenza virus itself and not because
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Table  4
Characteristics and course of illness in patients with and without oseltamivir treatment during pandemic inﬂuenza.
Oseltamivir treatment n = 65 No oseltamivir n = 20 Signiﬁcance, p-value
Age (median, years) 26.4 2.9 0.001
Underlying illness (% of patients) 78.5 45.0 0.004
ICU  admittance (% of patients) 35.4 10.0 0.047
Complications (% of patients) 53.8 35.0 NS
Duration of illness at admission (median, days) 2.0 3.5 0.024
Length of hospital stay (median, days) 6.0 2.0 0.006
ICU = intensive care unit. NS = not statistically signiﬁcant.
Table 5
Clinical characteristics, course of illness and treatment in patients with inﬂuenza B compared to seasonal and post-pandemic inﬂuenza A.
Seasonal inﬂuenza
A n = 47 (%)
Seasonal inﬂuenza
B n = 13 (%)
Post-pandemic
inﬂuenza A n = 45 (%)
Post-pandemic
inﬂuenza B n = 37 (%)
Underlying illness 41 (87.2) 10 (76.9) 36 (80.0) 31 (83.3)
ICU  admittance 12 (25.5) 4 (30.8) 10 (22.2) 10 (27.0)
Complications 18 (38.3) 6 (46.2) 18 (40.0) 17 (45.9)










































w* p = 0.043 post-pandemic inﬂuenza B versus post-pandemic inﬂuenza A.
f the occurrence of bacterial co-infection, although this is a
ell known complication of inﬂuenza. Still, more than two  thirds
f the patients during all seasons were treated with antibiotics.
lthough no signiﬁcant differences were observed in severity of
llness between the inﬂuenza seasons, more radiographic pneumo-
ia was diagnosed during the pandemic and post-pandemic period.
his is supported by in vitro data, which showed that inﬂuenza
(H1N1)pdm09 has an increased afﬁnity for 2, 3-linked recep-
ors on epithelial cells in the lower respiratory tract, in contrast to
easonal inﬂuenza subtypes.18
The majority of patients in our study had chronic under-
ying illness, regardless the season, emphasizing the impact of
nﬂuenza in these high risk groups, and the importance of yearly
nﬂuenza vaccination. Earlier reports recorded less comorbidi-
ies in patients admitted during the pandemic compared to other
nﬂuenza seasons.1,15 However, in our center, this was  only
bserved in patients under the age of 15 years. During the post-
andemic period, a similar pattern was observed. These ﬁndings
uggest that inﬂuenza A(H1N1)pdm09 can cause serious illness
specially in previously healthy young patients. It probably also
eﬂects the tertiary referral function of our hospital and might
ave biased our ﬁndings toward more complicated patients and
ore severe illness. However, the observed similarity in severity
f illness between patients with seasonal and pandemic inﬂuenza
s conﬁrmed by a recent study in which the estimated burden of
isease caused by pandemic inﬂuenza in the Netherlands, based on
ncidence, sequelae and mortality, was comparable with the burden
f seasonal inﬂuenza.19
Another ﬁnding of our study is the frequency of oseltamivir
reatment in patients with inﬂuenza infection. We  observed a
ore than tenfold increase in the use of oseltamivir during the
andemic compared to seasonal inﬂuenza. This was probably at
east partly due to national public health guidelines recommending
reatment with oseltamivir in hospitalized patients, a phenomenon
hat very recently also has been described for the United States.20
n contrast to the US-study however, where people above 65 years
ere less likely to receive antiviral agents, we  found that espe-
ially relatively healthy, young children who were already ill for
 couple of days and required only short term admission, did not
eceive oseltamivir. These ﬁndings suggest that during the pan-
emic these patients were admitted out of cautiousness rather than
ecause of the seriousness of illness. During the post-pandemic
eriod, oseltamivir was less frequently prescribed in patients
ith inﬂuenza A, although still signiﬁcant differences remainedcompared with seasonal inﬂuenza. The reasons for this remain
unclear. Compared to the pandemic, the use of oseltamivir was
much less advocated by national guidelines or professional stan-
dards. Besides, inﬂuenza A(H1N1)pdm09 was by then generally
regarded as causing relatively mild disease, possibly accounting for
more reluctance among physicians to start antiviral treatment. The
frequent use of oseltamivir did not lead to an upsurge of oseltamivir
resistance of the inﬂuenza virus, suggesting that other mechanisms
than antiviral pressure are responsible for the occurrence of resis-
tance. This is not unknown for inﬂuenza, as in recent years the
emergence of drug resistant inﬂuenza strains have been described
in the absence of antiviral drug pressure, e.g. adamantine resistant
inﬂuenza A(H3N2) since 2003 and oseltamivir resistant inﬂuenza
A(H1N1) since 2007.21
Inﬂuenza B caused illness similar to inﬂuenza A, regardless the
season. This is rather remarkable as previous studies showed that
inﬂuenza A(H3N2) was associated with highest annual rates of
inﬂuenza associated hospitalizations (with pneumonia, respiratory
and circulatory hospitalizations as discharge diagnoses) compared
to inﬂuenza A(H1N1) and inﬂuenza B.22 Despite similarity in
severity of illness, patients with inﬂuenza B during the post-
pandemic period were less treated with oseltamivir compared to
the patients with inﬂuenza A. This might be explained by the obser-
vation that patients with inﬂuenza B were admitted later in the
course of illness. Treatment with oseltamivir can shorten the dura-
tion of illness when given early (within 48 h) in the course of illness.
A limitation of our study is the relative small amount of patients
included, hospitalized in one single tertiary referral hospital. Larger
studies in different patient populations are necessary to conﬁrm
our ﬁndings.
In conclusion, in our center, seasonal, pandemic and post-
pandemic inﬂuenza showed many similarities with regard to
patients’ characteristics, severity of illness and clinical outcome.
Inﬂuenza in the post-pandemic period led to an equally severe
season in terms of number of patients admitted as compared to
the pandemic. Although the use of oseltamivir became common
practice, no increase in oseltamivir resistance was detected. Our
ﬁndings particularly highlight the fact that inﬂuenza is an impor-
tant cause of illness and death each year, and emphasizes the need
for inﬂuenza vaccination.Funding
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